Literature DB >> 35972671

Glibenclamide Directly Prevents Neuroinflammation by Targeting SUR1-TRPM4-Mediated NLRP3 Inflammasome Activation In Microglia.

Yihua He1, Yuan Chang1, Yuqin Peng1, Juan Zhu1, Kewei Liu1, Jiancong Chen1, Yongming Wu1, Zhong Ji1, Zhenzhou Lin1, Shengnan Wang1, Sohan Gupta1, Nailiang Zang1, Suyue Pan2, Kaibin Huang3.   

Abstract

Glibenclamide (GLB) reduces brain edema and improves neurological outcome in animal experiments and preliminary clinical studies. Recent studies also suggested a strong anti-inflammatory effect of GLB, via inhibiting nucleotide-binding oligomerization domain-like receptor containing pyrin domain 3 (NLRP3) inflammasome activation. However, it remains unknown whether the anti-inflammatory effect of GLB is independent of its role in preventing brain edema, and how GLB inhibits the NLRP3 inflammasome is not fully understood. Sprague-Dawley male rats underwent 10-min asphyxial cardiac arrest and cardiopulmonary resuscitation or sham-operation. The Trpm4 siRNA and GLB were injected to block sulfonylurea receptor 1-transient receptor potential M4 (SUR1-TRPM4) channel in rats. Western blotting, quantitative real-time polymerase chain reaction, behavioral analysis, and histological examination were used to evaluate the role of GLB in preventing NLRP3-mediated neuroinflammation through inhibiting SUR1-TRPM4, and corresponding neuroprotective effect. To further explore the underlying mechanism, BV2 cells were subjected to lipopolysaccharides, or oxygen-glucose deprivation/reperfusion. Here, in rat model of cardiac arrest with brain edema combined with neuroinflammation, GLB significantly alleviated neurocognitive deficit and neuropathological damage, via the inhibition of microglial NLRP3 inflammasome activation by blocking SUR1-TRPM4. Of note, the above effects of GLB could be achieved by knockdown of Trpm4. In vitro under circumstance of eliminating distractions from brain edema, SUR1-TRPM4 and NLRP3 inflammasome were also activated in BV2 cells subjected to lipopolysaccharides, or oxygen-glucose deprivation/reperfusion, which could be blocked by GLB or 9-phenanthrol, a TRPM4 inhibitor. Importantly, activation of SUR1-TRPM4 in BV2 cells required the P2X7 receptor-mediated Ca2+ influx, which in turn magnified the K+ efflux via the Na+ influx-driven opening of K+ channels, leading to the NLRP3 inflammasome activation. These findings suggest that GLB has a direct anti-inflammatory neuroprotective effect independent of its role in preventing brain edema, through inhibition of SUR1-TRPM4 which amplifies K+ efflux and promotes NLRP3 inflammasome activation.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cardiac arrest/cardiopulmonary resuscitation; Glibenclamide; Microglia; NLRP3 inflammasome; SUR1-TRPM4

Mesh:

Substances:

Year:  2022        PMID: 35972671     DOI: 10.1007/s12035-022-02998-x

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  57 in total

1.  Exploratory analysis of oral glibenclamide in acute ischemic stroke.

Authors:  Kaibin Huang; Yanhong Hu; Yongming Wu; Zhong Ji; Shengnan Wang; Zhenzhou Lin; Jiawei Xu; Suyue Pan
Journal:  Acta Neurol Scand       Date:  2019-06-14       Impact factor: 3.209

2.  Glibenclamide reduces secondary brain damage after experimental traumatic brain injury.

Authors:  K Zweckberger; K Hackenberg; C S Jung; D N Hertle; K L Kiening; A W Unterberg; O W Sakowitz
Journal:  Neuroscience       Date:  2014-04-30       Impact factor: 3.590

3.  Long-Term Outcomes in Patients Aged ≤70 Years With Intravenous Glyburide From the Phase II GAMES-RP Study of Large Hemispheric Infarction: An Exploratory Analysis.

Authors:  Kevin N Sheth; Nils H Petersen; Ken Cheung; Jordan J Elm; Holly E Hinson; Bradley J Molyneaux; Lauren A Beslow; Gordon K Sze; J Marc Simard; W Taylor Kimberly
Journal:  Stroke       Date:  2018-05-22       Impact factor: 7.914

4.  Glibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhage.

Authors:  J Marc Simard; Zhihua Geng; S Kyoon Woo; Svetlana Ivanova; Cigdem Tosun; Ludmila Melnichenko; Volodymyr Gerzanich
Journal:  J Cereb Blood Flow Metab       Date:  2008-10-15       Impact factor: 6.200

5.  Hemorrhagic transformation of ischemic stroke in diabetics on sulfonylureas.

Authors:  Hagen Kunte; Markus A Busch; Katrin Trostdorf; Bernd Vollnberg; Lutz Harms; Rupal I Mehta; Rudolf J Castellani; Pitchaiah Mandava; Thomas A Kent; J Marc Simard
Journal:  Ann Neurol       Date:  2012-11       Impact factor: 10.422

6.  Drugs acting on SUR1 to treat CNS ischemia and trauma.

Authors:  J Marc Simard; S Kyoon Woo; Sergei Bhatta; Volodymyr Gerzanich
Journal:  Curr Opin Pharmacol       Date:  2007-11-26       Impact factor: 5.547

7.  Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury.

Authors:  J Marc Simard; Orest Tsymbalyuk; Alexander Ivanov; Svetlana Ivanova; Sergei Bhatta; Zhihua Geng; S Kyoon Woo; Volodymyr Gerzanich
Journal:  J Clin Invest       Date:  2007-08       Impact factor: 14.808

8.  Newly expressed SUR1-regulated NC(Ca-ATP) channel mediates cerebral edema after ischemic stroke.

Authors:  J Marc Simard; Mingkui Chen; Kirill V Tarasov; Sergei Bhatta; Svetlana Ivanova; Ludmila Melnitchenko; Natalya Tsymbalyuk; G Alexander West; Volodymyr Gerzanich
Journal:  Nat Med       Date:  2006-03-19       Impact factor: 53.440

9.  Effect of IV glyburide on adjudicated edema endpoints in the GAMES-RP Trial.

Authors:  W Taylor Kimberly; Matthew B Bevers; Rüdiger von Kummer; Andrew M Demchuk; Javier M Romero; Jordan J Elm; Holly E Hinson; Bradley J Molyneaux; J Marc Simard; Kevin N Sheth
Journal:  Neurology       Date:  2018-11-16       Impact factor: 9.910

10.  Structures of the calcium-activated, non-selective cation channel TRPM4.

Authors:  Jiangtao Guo; Ji She; Weizhong Zeng; Qingfeng Chen; Xiao-Chen Bai; Youxing Jiang
Journal:  Nature       Date:  2017-12-06       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.